Compare LOCL & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOCL | NEUP |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | 333 | 8 |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 23.0M |
| IPO Year | N/A | N/A |
| Metric | LOCL | NEUP |
|---|---|---|
| Price | $1.12 | $4.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 23.4K | ★ 45.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $3.65 |
| 52 Week High | $5.75 | $21.31 |
| Indicator | LOCL | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 66.00 |
| Support Level | N/A | $3.92 |
| Resistance Level | $2.75 | $5.06 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 16.06 | 76.47 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.